Gehören Sie zu den Ersten, denen das gefällt!
Current advances in functional screening methodologies, medicinal chemistry, and structure-based drug design have generated large increases in the number and diversity of GPCR drug targets. Furthermore, basic research advances have opened the way for still further exploitation of this target class. This report:Explores current and likely consequences of recent advances concerning GPCR x-ray structures, allosteric interactions, multimerization, and functional selectivity; Extensively tabulates marketed drugs and compounds in development arranged by receptor type and subtype; Presents in-depth interviews with recognized experts in the field. G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development. Yet one can easily argue that the pharmacologic potential of GPCRs is far from exhausted. Currently approved drugs address only a few GPCRs. Technologic and scientific advances have resulted in R&D pipelines that target a great many more GPCRs than are represented among currently marketed products. In this report, we examine newer technologies used in GPCR pharmacology.